BLOG

Fierce-Biotech

AACR 2024: What Cancer Researchers Are Talking About

Florida-based Syncromune presented the first-ever clinical data from SYNC-T, a personalized platform therapy that uses a drug-device combination, in metastatic castration-resistant prostate cancer.